|
GLAXOSMITHKLINE : Regulatory update – Stiefel, a GSK company …
4-traders (press release) Stiefel, a GSK company, announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12 years of age or older. … Skin in the game: How Stiefel fits GSK's drug portfolio strategy |
View full post on acne skin treatment: Google Noticias
